Runcaciguat is a selective soluble guanylate cyclase (sGC) activator currently under investigation for its potential in treating chronic kidney disease, diabetic retinopathy, and associated cardiovascular… Read more
Runcaciguat is a selective soluble guanylate cyclase (sGC) activator currently under investigation for its potential in treating chronic kidney disease, diabetic retinopathy, and associated cardiovascular conditions. By targeting oxidized, heme-free sGC, this compound restores cyclic guanosine monophosphate (cGMP) signaling pathways that are often impaired by oxidative stress. To support precise analytical testing and method validation during development, researchers rely on high-quality reference standards. This category provides essential materials including related impurities, metabolites, and stable isotope-labelled compounds, which are critical for accurate quantification and rigorous impurity profiling. These analytical tools allow laboratories to maintain regulatory compliance and achieve consistent, reproducible results. By utilizing these specialized standards, analytical chemists can implement robust quality control protocols to characterize this sGC activator and its related substances throughout the pharmaceutical research and development lifecycle.